TD Cowen Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $20

Moomoo NewsApr 23 12:32 ET · Ratings

Arcutis Biotherapeutics: Buy Rating Affirmed Amid Positive Long-Term Outlook and Strategic Growth Potential

TipRanksApr 23 06:45 ET · Ratings

Here's Why Arcutis Biotherapeutics (NASDAQ:ARQT) Can Manage Its Debt Despite Losing Money

Simply Wall StApr 22 09:12 ET

Arcutis to Report First Quarter 2025 Financial Results and Host Conference Call on May 6, 2025

GlobeNewswireApr 17 08:00 ET

Arcutis Biotherapeutics Promotes Vairavan to CFO as Topper Plans Retirement

WSJApr 10 17:41 ET

Arcutis Biotherapeutics: Topper Will Continue to Serve as CFO Until 1Q 10-Q Filing, Provide Transition Support >ARQT

Dow JonesApr 10 16:34 ET